Raise awareness of environmental health issues in order to better protect our children and future generations.

EMF Studies

21 April 2015

New Statin Study Confirms Scary Link to Diabetes

MDs promote statins for everyone with diabetes.  A new study from Finland concludes that statin treatment increased the risk of type 2 diabetes by 46%, attributable to decreases in insulin sensitivity and insulin secretion.  Following this article is the abstract of the study.

New Statin Study Confirms Scary Link to Diabetes
by Joe Graedon, People's Pharmacy, 20 April 2015

Do statins raise blood sugar and increase the risk of diabetes? A new study says the risk of diabetes is substantially greater than previously reported.

In 2003 People’s Pharmacy Readers Were Alerted

We received a signal from readers more than a decade ago that statins could trigger diabetes in people with normal blood sugar and make control of diabetes more challenging in people who already had the disease.

As long ago as 2003 we began getting messages like this one:

“Since we started on Lipitor, our blood sugar has been rising rapidly. My husband asked the doctor about changing to Tricor, but he was told it would not help him much and he should stay with Lipitor. It seems that Lipitor is affecting our blood sugar. Is this possible?”

At that time most physicians did not believe statins could affect blood sugar. We scoured the official prescribing information for atorvastatin (Lipitor) and found hidden away in a long list of other possible adverse reactions the word “hyperglycemia.” In other words, elevated blood sugar. But this side effect was buried along with lots of other seemingly rare complications. Most patients were never warned that there was a connection between Lipitor and blood sugar elevations.



JUPITER and Diabetes: Dodging and Weaving

In 2008 a study called JUPITER (New England Journal of Medicine, Nov. 8, 2008) revealed a link between rosuvastatin (Crestor) and type 2 diabetes. Nowhere in the abstract or the conclusions was there mention of this connection. That is what busy doctors often look at rather than read the entire article.

If, however, you took the time to actually review the full results you discovered that although the authors downplayed the risk of elevated blood sugar they admitted that,“Nevertheless, physician-reported diabetes was more frequent in the rosuvastatin group (270 reports of diabetes, vs. 216 in the placebo group…”

In the discussion the authors admitted that:

“We did detect a small but significant increase in the rate of physician-reported diabetes with rosuvastatin, as well as a small, though significant, increase in the median value of glycated hemoglobin [HbA1c]. Increases in glucose and glycated hemoglobin levels, the incidence of newly diagnosed diabetes, and worsening glycemic [blood sugar] control have been reported in previous trials of pravastatin, simvastatin, and atorvastatin. However, systematic protocol-specified measurements showed no significant difference between our two study groups in fasting blood glucose levels or glycosuria during the follow-up period. Therefore, although the increase in the rate of physician-reported diabetes in the rosuvastatin group could reflect the play of chance, further study is needed before any causative effect can be established or refuted.”

Granted, this is doctorspeak and somewhat hard to decipher. We interpret their analysis as attempting to downplay the risk. The seeds of doubt are planted with the phrase “could reflect the play of chance.” And indeed some cardiologists chose to either ignore or minimize the connection between rosuvastatin (and other statins) and diabetes.

MDs Promote Statins for Everyone with Diabetes

The American College of Cardiology (ACC), the American Heart Association (AHA) and the American Diabetes Association have all come out strongly in favor of statin therapy. In fact the ACC and the AHA published a “Risk Calculator“ that pretty much requires all physicians to prescribe a statin to anyone with diabetes.

When we have asked cardiologists at the top of the pecking order whether statins might trigger diabetes or make it worse, we were told that it is nothing to worry about and that the benefits of statins far outweighed any risks.

The Straight & Skinny on Statins

Almost seven years after the JUPITER trial was published, we have accumulating evidence that statin use is indeed linked to diabetes. In most of the clinical trials there wasn’t much incentive to look for this connection because it was not anticipated. Even so, going back and reviewing 13 studies revealed that there was a signal.
The Finns Spill the Beans

The most recent study tracked 8,749 Finnish men between the ages of 45 and 73. None had diabetes at the start of the trial. They were followed for nearly six years. Here is what they found:

“Our study reports several novel findings: (1) statin therapy was associated with a 46% increased risk of type 2 diabetes after adjustment for confounding factors, suggesting a higher risk of diabetes in the general population than previously reported; (2) statin therapy was associated with a worsening of hyperglycaemia, especially 2 h glucose; (3) statin therapy was associated with a 24% reduction in insulin sensitivity and 12% reduction in insulin secretion compared with individuals without statin therapy and (4) both simvastatin and atorvastatin treatment was associated with reduced insulin sensitivity and insulin secretion in a dose-dependent manner.

“In our study statin therapy was associated with a higher risk of diabetes (46%) than previously reported.”

The Bottom Line on Statins and Diabetes

There is no longer any doubt that statin-type cholesterol-lowering drugs like atorvastatin (Lipitor), lovastatin (Mevacor), rosuvastatin (Crestor) and simvastatin (Zocor) can trigger diabetes. And based on the Finnish trial, these drugs make it harder to to control blood sugar. Perhaps most convincing to a pharmacologist like me, the higher the dose, the worse the problem. In other words, a dose-related problem usually signals that the adverse effect is caused by the drugs and is not merely “chance.”

As we mentioned at the top of the page, the most worrisome complications of diabetes are cardiovascular: heart attacks and strokes. Statins are supposed to lower the risks of such events. But if statins increase the risk of diabetes, then almost by definition the drugs are also increasing the risks of the very outcomes they are supposed to be preventing. It would be like trying to climb a hill with lead overshoes. Another analogy we like: driving with your feet on the gas and the brake simultaneously. You will not make much progress this way.

No one should ever stop any medication without consulting with the prescribing physician. That is certainly the case in this situation. Nevertheless, we encourage people who are taking statins to share the latest Finnish research with their health care professionals.

And we very much want to learn from you. Have you had diffilculties with blood glucose while taking a statin-type drug or have you avoided such problems? Please share your story below in the “WHAT DO YOU THINK?” section. And please vote on this article at the top of this page.

Anyone who would like to learn more about alternative approaches to controlling cholesterol and improving heart health will find our book, Best Choices from the People’s Pharmacy, of interest.

Following is the Abstract of the Finnish study:

Diabetologia. 2015 May;58(5):1109-17. doi: 10.1007/s00125-015-3528-5. Epub 2015 Mar 10.

Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort.

Cederberg H1, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M.

Author information

Abstract

AIMS/HYPOTHESIS:
The aim of this work was to investigate the mechanisms underlying the risk of type 2 diabetes associated with statin treatment in the population-based Metabolic Syndrome in Men (METSIM) cohort.

METHODS:
A total of 8,749 non-diabetic participants, aged 45-73 years, were followed up for 5.9 years. New diabetes was diagnosed in 625 men by means of an OGTT, HbA1c ≥6.5% (48 mmol/mol) or glucose-lowering medication started during the follow-up. Insulin sensitivity and secretion were evaluated with OGTT-derived indices.

RESULTS:
Participants on statin treatment (N = 2,142) had a 46% increased risk of type 2 diabetes (adjusted HR 1.46 [95% CI 1.22, 1.74]). The risk was dose dependent for simvastatin and atorvastatin. Statin treatment significantly increased 2 h glucose (2hPG) and glucose AUC of an OGTT at follow-up, with a nominally significant increase in fasting plasma glucose (FPG). Insulin sensitivity was decreased by 24% and insulin secretion by 12% in individuals on statin treatment (at FPG and 2hPG <5.0 mmol/l) compared with individuals without statin treatment (p < 0.01). Decreases in insulin sensitivity and insulin secretion were dose dependent for simvastatin and atorvastatin.

CONCLUSIONS/INTERPRETATION:
Statin treatment increased the risk of type 2 diabetes by 46%, attributable to decreases in insulin sensitivity and insulin secretion.

PMID: 25754552 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/25754552

No comments:

Post a Comment